The data above show that the antitumor response induced by intratumor treatment with mRNA encoding MLKL can lead to priming of tumor xeno-antigen-specific CD8+ and CD4+ T cells and to the elimination of cells that display this antigen. The gene discussed is CD8A; the disease is neoplasm.